SAN FRANCISCO, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for ...
SAN FRANCISCO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for ...
Structure Therapeutics Inc. earns a Strong Buy rating following robust phase 2b data for oral GLP-1R agonist Aleniglipron in obesity. Aleniglipron achieved placebo-adjusted weight loss up to -15.3% at ...
In business, the power of individual leaders is an inherently hard thing to measure. It’s subjective, and it fluctuates on ...
The quality of AI-generated artifacts and answers improves when certificates are demanded, even if the evidence provided by ...
Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation Placebo-adjusted mean weight ...
Since 2013, there have been metaphorically for programmers to build annual rankings of the world’s most popular programming languages. The rankings have traditionally relied on public signals such as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback